Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Additional Infanrix Hexa dose after allogeneic stem cell transplantation in M3 non-responders
2017-003523-30Phase 3Terminated
- Sponsor
- CHU Grenoble Alpes
- Start
- Mar 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pertussis filamentous haemagglutinin in Vaccine-preventable disease (VPD) (3 arms), sponsored by CHU Grenoble Alpes. Started Mar 2018; status: terminated.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
Vaccine-preventable disease (VPD)
Beyond the preview
Go deeper on 2017-003523-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003523-30.